


PHARMACEUTICAL 2021

assemblybio

ASSEMBLY BIOSCIENCES INC. Rank 109 of 409





PHARMACEUTICAL 2021



ASSEMBLY BIOSCIENCES INC. Rank 109 of 409

The relative strengths and weaknesses of ASSEMBLY BIOSCIENCES INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ASSEMBLY BIOSCIENCES INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 142% points. The greatest weakness of ASSEMBLY BIOSCIENCES INC. is the variable Research and Development, reducing the Economic Capital Ratio by 94% points.

The company's Economic Capital Ratio, given in the ranking table, is 7.5%, being 362% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	224,493
Cost of Goods Sold	0
Intangible Assets	12,638
Liabilities, Current	24,433
Liabilities, Non-Current	15,712
Other Assets	44,523
Other Compr. Net Income	-69
Other Expenses	0
Other Liabilities	2,531
Other Net Income	2,624
Property and Equipment	1,600
Research and Development	106,823
Revenues	79,105
Selling, General and Administrative Expense	37,058

Output Variable	Value in 1000 USD
Assets	283,254
Liabilities	42,676
Expenses	143,881
Stockholders Equity	240,578
Net Income	-62,152
Comprehensive Net Income	-62,186
Economic Capital Ratio	7.5%